Dr. Matthew Yurgelun, assistant professor of medicine at Harvard Medical School and gastrointestinal medical oncologist at the Dana Farber Gastrointestinal Cancer Center and Cancer Genetics and Prevention Program, presents information on the recently approved nivolumab for the treatment of patients 12 years and older with mismatch repair deficient and microsatellite instability high metastatic colorectal cancer.
